CTI BIOPHARMA CORP (CTIC) Stock Price, Forecast & Analysis
USA - NASDAQ:CTIC - US12648L6011 - Common Stock
CTIC Key Statistics, Chart & Performance
The current stock price of CTIC is 9.09 USD. In the past month the price increased by 1%. In the past year, price increased by 56.19%.
CTIC Latest News, Press Relases and Analysis
CTIC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.14 | 386.36B | ||
| AMGN | AMGEN INC | 14.8 | 174.25B | ||
| GILD | GILEAD SCIENCES INC | 14.43 | 146.60B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.26 | 107.99B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.55 | 69.40B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 866.08 | 57.90B | ||
| INSM | INSMED INC | N/A | 40.57B | ||
| NTRA | NATERA INC | N/A | 28.36B | ||
| BIIB | BIOGEN INC | 9.33 | 22.91B | ||
| INCY | INCYTE CORP | 16.51 | 20.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.2 | 20.53B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.89 | 14.88B |
Related stock screener links
About CTIC
Company Profile
CTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. The company is headquartered in Seattle, Washington and currently employs 128 full-time employees. The firm is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). The company is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). The company also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. The company is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (ISTs), such as the ongoing maintenance therapy trial in patients with ovarian cancer.
Company Info
CTI BIOPHARMA CORP
3101 Western Ave Ste 800
Seattle WASHINGTON 98121 US
CEO: Adam R. Craig
Employees: 128
Phone: 12062827100.0
CTI BIOPHARMA CORP / CTIC FAQ
What does CTIC do?
CTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. The company is headquartered in Seattle, Washington and currently employs 128 full-time employees. The firm is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). The company is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). The company also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. The company is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (ISTs), such as the ongoing maintenance therapy trial in patients with ovarian cancer.
Can you provide the latest stock price for CTI BIOPHARMA CORP?
The current stock price of CTIC is 9.09 USD.
Does CTIC stock pay dividends?
CTIC does not pay a dividend.
What is the ChartMill technical and fundamental rating of CTIC stock?
CTIC has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the employee count for CTIC stock?
CTI BIOPHARMA CORP (CTIC) currently has 128 employees.
What is the ownership structure of CTI BIOPHARMA CORP (CTIC)?
You can find the ownership structure of CTI BIOPHARMA CORP (CTIC) on the Ownership tab.
CTIC Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to CTIC. When comparing the yearly performance of all stocks, CTIC is one of the better performing stocks in the market, outperforming 97.78% of all stocks.
CTIC Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CTIC. Both the profitability and financial health of CTIC have multiple concerns.
CTIC Financial Highlights
Over the last trailing twelve months CTIC reported a non-GAAP Earnings per Share(EPS) of -0.58. The EPS increased by 52.46% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CTIC Forecast & Estimates
14 analysts have analysed CTIC and the average price target is 10.7 USD. This implies a price increase of 17.66% is expected in the next year compared to the current price of 9.09.
For the next year, analysts expect an EPS growth of 66.63% and a revenue growth 121.03% for CTIC